Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

[1]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[2]  Xinmin Zhang,et al.  The satisfactory reproducibility of the Ki-67 index in breast carcinoma, and it's correlation with the recurrence score , 2014 .

[3]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[4]  G. Hortobagyi,et al.  Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy , 2013 .

[5]  C. Caldas,et al.  A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial , 2013, British Journal of Cancer.

[6]  Hiroshi Ishiguro,et al.  Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. , 2012, European journal of radiology.

[7]  J. Donohue,et al.  Number of lymph nodes identified at axillary dissection , 2010, Cancer.

[8]  R. Gelber,et al.  Facilitating consensus by examining patterns of treatment effects. , 2009, Breast.

[9]  F. Penault-Llorca,et al.  Measurement of residual disease after neoadjuvant chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Edith A Perez,et al.  Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Neven,et al.  Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .

[14]  Terry L. Smith,et al.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Huiman X Barnhart,et al.  Overall Concordance Correlation Coefficient for Evaluating Agreement Among Multiple Observers , 2002, Biometrics.

[16]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .